Merck Strikes $1 Billion+ Deal With Janux TherapeuticsBusiness, Cancer, Clinical Trials, Deals, Intellectual Property, Product Pipeline, R&D, T cell engager immunotherapies, Tumor Cells, TumorsSan Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer. Read more December 18, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/12/Merck-Strikes-1B-Deal-to-Leverage-Januxs-T-Cell-Engager-Program-Against-Cancer-BioSpace-12-18-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-12-18 12:00:312020-12-19 22:37:56Merck Strikes $1 Billion+ Deal With Janux Therapeutics